ICER's evaluation of Vertex Pharmaceuticals' non-opioid pain drug, Journavx, finds cost-effectiveness related to potential ...

BofA raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $567 from $555 and keeps a Buy rating on the shares. After having ...

Vertex Pharmaceuticals (NasdaqGS:VRTX) saw a notable 20.53% share price increase over the last quarter, which coincided with several key developments in its Type 1 Diabetes (T1D) initiatives. The ...

According to a Vertex spokesperson, the drug is seeing strong initial market adoption, with growing payer coverage and ...

We recently published a list of 8 Best Gene-Editing Stocks to Buy. In this article, we are going to take a look at where ...

Despite a $400 million impairment charge, analysts say the removal of a drug-device combo from its portfolio is not a huge ...

The economy has been on shaky ground for a while, and President Trump's tariffs and trade wars could finally send it into a ...

Vertex Pharmaceuticals: Up 18% Pharma stock Vertex ... and with the FDA approval of its non-opioid pain medication Journavx in January, more growth could be on the way. The company's highly ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $478.12, a high ...

In a report released today, William Pickering from Bernstein maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), with ...

Shares of Vertex Pharmaceuticals Inc. VRTX slipped 1.60% to $484.82 Monday, on what proved to be an all-around favorable ...